Patent application number | Description | Published |
20080213274 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE - The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA). | 09-04-2008 |
20090010922 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P. | 01-08-2009 |
20090011490 | IMMUNOGENIC MINICELLS AND METHODS OF USE - The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject. | 01-08-2009 |
20090074720 | METHODS FOR DECREASING IMMUNE RESPONSE AND TREATING IMMUNE CONDITIONS - The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA). | 03-19-2009 |
20090074789 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS - The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate. | 03-19-2009 |
20090130099 | HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 05-21-2009 |
20090130100 | METHODS OF USING HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 05-21-2009 |
20090136483 | Compositions and Methods for Binding Lysophosphatidic Acid - Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. | 05-28-2009 |
20090137037 | NUCLEIC ACIDS CODING FOR HUMANIZED ANTIBODIES FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 05-28-2009 |
20090148443 | HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 06-11-2009 |
20090220523 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY AND NEOVASCULARIZATION CONDITIONS - The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of the bioactive lipids. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphinxine-1-phosphate (S1P) or lysophosphophatidic acid (LPA). | 09-03-2009 |
20100003242 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P. | 01-07-2010 |
20100034814 | COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID - Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence. | 02-11-2010 |
20100098700 | PHARMACEUTICAL COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P. | 04-22-2010 |
20100226916 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS - The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate. | 09-09-2010 |
20100292443 | Humanized platelet activating factor antibody design using anti-lipid antibody templates - Methods for designing a humanized antibody to platelet activating factor are provided. These methods may be performed in silico. | 11-18-2010 |
20110020319 | USE OF ANTI- SPHINGOSINE-1-PHOSPHATE ANTIBODIES IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS - The present invention relates to use of anti-S1P antibodies in combination with chemotherapeutic agents for treatment and/or prevention of cancer, tumor growth, metastasis and/or growth of metastatic tumors. | 01-27-2011 |
20110044990 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - The present invention provides crystalline forms of an anti-lipid antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided. The lipid may be a bioactive lipid, including sphingolipids such as S1P. X-ray coordinates of such a crystal are provided, as are methods of using this information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided. | 02-24-2011 |
20110064744 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods for preventing or treating pain are provided, comprising administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA. | 03-17-2011 |
20110076267 | HUMANIZED ANTIBODY COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID - Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described. | 03-31-2011 |
20110118443 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them. | 05-19-2011 |
20110212088 | ANTI-PAF ANTIBODIES - Monoclonal antibodies to platelet activating factor (PAF) are described, along with methods for their production and use. Such antibodies can be formulated and used for therapeutic purposes, as well as for diagnosis and detection. | 09-01-2011 |
20110281330 | MINICELLS EXPRESSING ANTIBODIES OR DERIVATIVES THEREOF AND COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS - Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell. | 11-17-2011 |
20120014944 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody. | 01-19-2012 |
20120014946 | PREVENTION AND TREATMENT OF PAIN USING MONOCLONAL ANTIBODIES AND ANTIBODY FRAGMENTS TO LYSOPHOSPHATIDIC ACID - Methods for preventing and treating pain are provided. These methods involve administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA. Preferably, antibody is a humanized anti-LPA monoclonal antibody, or an antigen-binding fragment derived from such an antibody. | 01-19-2012 |
20120082665 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO SPHINGOSINE-1-PHOSPHATE - The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain. | 04-05-2012 |
20120135503 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell. | 05-31-2012 |
20120142079 | MINICELL BASED DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell. | 06-07-2012 |
20120195901 | Compositions and Methods for Binding Lysophosphatidic Acid - Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. | 08-02-2012 |
20120252099 | IMMUNOGENIC MINICELLS AND METHODS OF USE - The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject. | 10-04-2012 |
20130034545 | TREATMENT OF TRAUMATIC BRAIN INJURY USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods are provided for treating traumatic brain injury (TBI) using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies. In particular, the TBI may be blast-induced TBI (bTBI) such as commonly occurs in battlefield injuries. The treatment may include functional locomotor recovery. | 02-07-2013 |
20130202586 | STEM CELL THERAPY USING INHIBITORS OF LYSOPHOSPHATIDIC ACID - Methods are provided for stem cell therapy using inhibitors of lysophosphatidic acid (LPA). Inhibition of LPA may be direct or indirect; particularly preferred direct inhibitors of LPA are antibodies to LPA, including humanized monoclonal antibodies to LPA. Such inhibitors are used in combination with stem cells for the treatment of injuries, diseases, or conditions amenable to treatment by stem cell therapy. | 08-08-2013 |
20130261287 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them. | 10-03-2013 |
20130302831 | METHODS AND KITS FOR DETECTING AND DIAGNOSING NEUROTRAUMA - Methods and kits for detecting and diagnosing neurotrauma (e.g., traumatic brain injury, stroke, or spinal cord injury) are provided. These methods rely on the determination of lysophosphatidic acid (LPA) and/or LPA metabolite levels in patient samples following suspected injury. | 11-14-2013 |
20130344087 | COMBINATIONS OF ANTI-S1P ANTIBODIES AND SHPINGOLIPID PATHWAY INHIBITORS - Methods for administering combinations of compositions comprising anti-S1P antibodies or antibody fragments and modulators of sphingolipid metabolic pathway enzymes are described. Such methods allow aberrant or undesirable levels of S1P to be reduced in patients known or suspected to have a disease or disorder correlated with aberrant S1P levels, and thus will be useful in treating such diseases and disorders. | 12-26-2013 |
20140186339 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS - The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions, particularly glaucoma and ocular hypertension. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate. | 07-03-2014 |
20140199293 | HUMANIZED ANTIBODY COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID - Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described. | 07-17-2014 |
20150031055 | NOVEL BIOACTIVE LIPID DERIVATIVES, AND METHODS OF MAKING AND USING THE SAME - Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described. | 01-29-2015 |